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Abstract 
Long Term AMPK Activation Limits Obesity Induced Muscle Atrophy 
 
Joshua C. Drake 
 
The aim of this study was to identify obesity-induced alterations in regulatory 
mechanisms of skeletal muscle mass and how they would be altered with long 
term (8 weeks) AMPK-agonist treatment.  8 week old male, lean (L) wild type 
[body weight (BW) = 26.9 g] and ob/ob (O) [BW = 46.2 g] mice were fed an AMP 
kinase (AMPK) activator, β-GPA (F), mixed at a 1% concentration within their 
food or normal chow as control (C) for 8 weeks.  Following an overnight (12 hr) 
fast, all mice were sacrificed and the gastrocnemius complex was excised for 
analysis.  Muscle mass was lower in the OC mice (121.08 ± 9.3 mg) versus LC 
(158.4 ± 5.6 mg).  This corresponded with decreases in raptor associated with 
mTOR. Following treatment, western analysis of OF muscle lysates displayed 
increased AMPK and acetyl-CoA carboxylase phosphorylation compared with LC 
and OC mice.  OC mice displayed higher activation of mammalian Target of 
Rapamycin (mTOR)-regulated signaling (S6K1, 4E-BP1, and GSK3), which was 
reciprocally altered after 8 weeks of β-GPA feeding.  These data show that long 
term (8 week) AMPK-agonist treatment can augment obesity-induced alterations 
in regulatory mechanisms of skeletal muscle mass through the normalization to 
lean levels of mTOR signaling. 
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Chapter 1:  Specific Aims and Hypotheses 
Introduction to the Problem 
 Obesity has recently moved to the forefront of health care concerns in the 
United States.  Many of the health problems associated with obesity like 
lipotoxicity, dyslipidemia, type 2 diabetes and chronic inflammation have 
significant impacts on skeletal muscle function.  These decreases in function 
impact the activity level, independence, and quality of life of an individual.  This 
decrease in function is due to muscle atrophy induced by obesity (54).  Loss in 
muscle mass is due to an imbalance between the protein synthesis and 
degradation rates (3).  Mammalian Target of Rapamycin (mTOR) increases RNA 
translation and protein synthesis initiating growth.  As growth is an energetically 
expensive process, mTOR responds in the presence of adequate nutrients (4, 5, 
41, 68, 84).  Obesity is a state of excessive nutrients and displays elevated 
mTOR signaling, however, skeletal muscle atrophy is present (6, 27, 38, 63, 67, 
72).  AMP-activated protein kinase (AMPK), a sensor of low energy and 
malnutrition, inhibits the mTOR pathway and promotes oxidative metabolism.  
While numerous studies have examined AMPK in relation to metabolic 
complications during obesity, it remains unclear how therapies activating AMPK 
and/or repressing highly activated mTOR will improve obesity-induced muscle 
atrophy.  Understanding this dysregulation and how AMPK activation affects 
growth signaling will provide insights towards new and innovative ways to treat 
and prevent the problem of obesity, resulting in improved quality of life in these 
individuals and lower health care costs.  
 
Specific Aims and Hypothesis 
The objectives of this study are to: (1) evaluate the effectiveness of AMPK 
agonist treatment on skeletal muscle growth and protein formation during 
obesity; (2) identify the central regulatory pathway that contributes to muscle 
atrophy induced by obesity. The central hypothesis of this study is that 
AMPK activation can improve obesity-induced skeletal muscle atrophy by 
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augmenting growth signaling.  We will test the central hypothesis and 
accomplish the objectives of this study by pursuing the following specific aims: 
1. Determine the role of AMPK activation on skeletal muscle mass and 
morphology within obese muscle.  Our hypothesis is that 8 weeks of β-
GPA (AMPK agonist) feeding will activate AMPK, increasing total muscle 
mass relative to body weight and tibial length by enhancing accretion of 
protein in obese skeletal muscle. 
2. Determine how obesity alters mTOR-related signaling in skeletal muscle 
and evaluate the benefit of AMPK activation.  Our hypothesis is that 
activated AMPK will subsequently improve growth related signaling, such as 
Akt, by reducing the activation of mTOR substrates S6K1 and 4E-BP1 and 
promote proper ratio of mTOR with raptor and eIF4F complex formation in 
fasted obese skeletal muscle. 
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Chapter 2:  Background and Significance 
Obesity and Insulin Resistance  
Obesity has become a major medical concern in most of the developed 
world, particularly, in the United States. The Center for Disease Control and 
Prevention (CDC) define obesity as a body mass index (BMI) ≥ 30.  Over the 
past 20 years the US has seen a significant increase in the amount of the 
population that fits this criterion.  In 2008, thirty-two states showed a 25% or 
greater prevalence of obesity among their populations.  Six of those (Alabama, 
Mississippi, Oklahoma, South Carolina, Tennessee, and West Virginia) showed 
that 30% or greater of their population had a BMI of at least 30 (2).  
 
Insulin Resistance 
 Insulin resistance is commonly associated with excessive weight gain 
and/or hyperlipidemia, i.e. obesity (43).  Using the homeostasis model 
assessment index (HOMA) and glucose sensitivity index (Si) on obese and lean 
subjects showed that the HOMA was 2.3 fold higher in obese compared to the 
lean and the Si was 2.1 higher in the lean compared to the obese subjects (57).  
Insulin resistance is also associated with an increase in several pancreatic 
peptides other than just insulin, such as amylin (an insulin complement that 
regulates glucose appearance), glucagon (important in carbohydrate 
metabolism), and gastric inhibitory polypeptide (helps induce insulin secretion) 
(57). 
 
Glucose uptake into skeletal muscle accounts for approximately 80% of 
the total insulin-stimulated glucose disposal (81).  Because of this, skeletal 
muscle is heavily linked to the development of the insulin resistance that leads to 
type 2 diabetes (39).  The primary means by which glucose enters skeletal 
muscle is by the Glut 4 transport protein (39).  In obese men and diabetic rats, 
Glut 4 has lower expression when compared to lean controls (21, 39).  Glut 4 
expression is also fiber type-dependent.  He et al. (28) proposed that a muscle 
fiber’s sensitivity to insulin was dependent on the fiber type with type I being the 
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most sensitive, followed by type IIa then IIb.  Using Sprague-Dawley rats, at 
physiological insulin concentration, red (type I) muscle transports twice as much 
glucose as white (type II) muscle (39).  From basal insulin concentrations to 
maximum concentration, type II skeletal muscle shows only a 6x increase in 
glucose transport compared to a 17x increase in type I skeletal muscle fibers 
(39).  Type I fibers also contain 5.2x more Glut4 mRNA as well as total protein 
when compared to type II fibers (39).  
 
Fatty acids 
Obese human subjects display significant increases in endogenously 
synthesized long-chain fatty acid species C16:0, C16:1, C18:1 (57).  This 
increase in the fatty acid pool represents the fatty acids circulating in triglycerides 
or other esterified species.  Because of this, obese subjects display higher 
triglyceride levels when compared to lean cohorts (57).  Increases in circulating 
triglycerides are central in the pathogenesis for their accumulation within skeletal 
muscle (47, 74), known as intramuscular triglycerides (IMTG).  Both in vitro and 
in vivo exposure of skeletal muscle to increased lipids, (ex. high fat diet or lipid 
infusion) results in an accumulation of IMTG (21, 28, 35, 43, 94).  This 
corresponds with the increase in IMTG that is seen within the skeletal muscle of 
obese and type 2 diabetic subjects when compared to lean controls (21, 23, 43, 
88, 94).  There is a fiber type-specific accumulation that occurs in association 
with obesity and type 2 diabetes in that IMTG are further elevated in the type I 
fibers (23).  For example, in soleus muscles (comprised primarily of type I fibers) 
of obese adolescent males showed an increase in IMTG (74). An increase in 
IMTG depends on several factors: the availability and efficiency of fatty acid 
uptake, the rate of fatty acid oxidation, and the rate of synthesis and hydrolysis of 
triacylglycerides (94). 
 
A large proportion of fatty acid oxidation, referred to as β-oxidation, occurs 
within the skeletal muscle or more specifically within the mitochondria (88).  
Regulation of mitochondrial function is believed to be through peroxisome 
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proliferators-activated receptor gamma coactivator 1-alpha (PGC-1α) (11). 
Cultured myotubes from type 2 diabetic patients display mitochondrial 
dysfunction which is believed to be caused by disturbances that occur 
downstream of β-oxidation (94).  Thus, during increases in fatty acid influx or β-
oxidation there is corresponding increase in production and release of acid 
soluble metabolites that result in the increases in IMTG seen in obesity and type 
2 diabetes (94).  When these myotubes from type 2 diabetic patients are 
exposed to elevated fatty acids, PGC-1α (a key factor in β-oxidation) gene 
expression is increased but the response is blunted (94). PGC-1α coactivator 
peroxisome proliferators-activated receptor (PPARγ) and mitochondrial marker 
cytochrome c oxidase IV (COXIV) are significantly reduced in the muscles of 
raptor (a component of mTOR essential for proper muscular growth) knock out 
mice linking its functions to that of muscle growth (4). 
 
Lipolysis is the catabolic reaction that breaks down one molecule of TAG 
into three fatty acid molecules (56).  When dysregulation of lipolysis of IMTG is 
present there is an increase in the amount of diacylglycerides (DAG).  Moro et al 
(56) compared the hydrolysis of TAG and DAG and found an imbalance that 
resulted in a higher rate of TAG hydrolysis compared to DAG hydrolysis, which 
caused DAG to accumulate.  The dysregulation of lipolysis just mentioned is also 
responsible for the creation of new ceramides within the skeletal muscle (56).  
Ceramides and DAG are both associated with the lipotoxicity that is found in 
obese and type 2 diabetic populations (56, 97), although DAG is believed to be 
the most influential of the two.  Ceramides have been shown to not change 
following a 5hr lipid infusion (97), however, this could be due to the period of 
infusion not being long enough.  Therefore, it is not IMTG themselves that 
contribute to insulin resistance but rather impairments in the way they are broken 
down.     
 
A high fat diet increases IMTG but it also decreases insulin stimulated 
skeletal muscle glucose uptake (58).  The dysregulation of lipolysis through 
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increases in circulating free fatty acids and the subsequent accumulation of 
IMTG is integral in the pathogenesis of insulin resistance by inhibiting glucose 
transport (47, 68). This manifests as a decrease in glucose oxidation and the 
synthesis of glycogen within skeletal muscle (68). Intramuscular glucose-6-
phosphate concentration, whose release is insulin dependent and vital in 
glycolysis within the muscle, is lowered below baseline values in nine healthy 
human subjects following lipid infusion (68), further suggesting that fatty acids 
play an inhibitory role in glucose transport.  
 
 Further investigation into the signaling behind insulin resistance shows 
that increases in plasma fatty acids inhibit insulin activation of insulin receptor 
substrate 1 (IRS-1) associated PI3-kinase at the level of IRS-1 (97).  A 30% 
reduction in IRS-1 tyrosine phosphorylation and a 50% reduction in IRS-1 
associated PI3-kinase activity is observed in rats following 5 hrs of lipid infusion 
(97).  The reduction in insulin activation of IRS-1 associated PI3-kinase activity 
coincides with activation of the enzyme Protein Kinase C that is believed to be 
responsible for the inhibition of IRS-1.  PKC-θ needs DAG for activation, which is 
already elevated during obesity and type 2 diabetes (56, 97) so the role of PKC-θ 
in the inhibition of IRS-1 associated PI3-kinase activity is likely. 
 
Obesity and Muscle 
Muscle Size 
In obesity the mass of the muscle in proportion with body size is reduced, 
significantly impacting the function of skeletal muscle.  When comparing 74 
obese human subjects (BMI ≥ 30 kg/m2) to 67 lean subjects (BMI < 25 kg/m2), 
the obese subjects had twice as much total fat mass as the lean controls, but 
only a 17% increase in lean mass (57).  This corresponded to 60% of the obese 
subjects’ body weight being made up of muscle compared to 71% in the lean 
controls (57).  This trend is also visible in mice and is specific to the muscle (38).  
In ob/ob mice the sternomastoid, extensor digitorum longus (EDL), and soleus 
muscles are 30%, 21%, and 13% smaller, respectively, when compared to lean 
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controls (38).  This corresponded to a muscle mass-to-body mass ratio of -62% 
for the sternomastoid, -56% for the EDL, and -52% for the soleus compared to 
lean controls.  These smaller muscle sizes in obese mice were also associated 
with smaller fiber size by examining the cross sectional areas, except in the 
soleus where the cross sectional area was similar between ob/ob and lean mice 
(38).    
 
Satellite Cells 
 During normal turnover in skeletal muscle, myofiber nuclei are lost.  The 
maintenance and replacement of these nuclei is the role of satellite cells.  
Satellite cells are normally found between the basal lamina and the sarcolemma 
of the myofibrils.  Hypertrophy of skeletal muscle depends on proper function of 
these satellite cells (62).  Obese Zucker rats, an insulin resistant obese model, 
show a decrease in the amount of myonuclei compared to lean cohorts, 
evidenced by BrdU staining on plantaris and soleus muscle (62).  Similar findings 
have been seen in the ob/ob mouse.  Myofibers in 3-week-old ob/ob mice had 
less satellite cell proliferative activity than did lean controls (63). 
 
Muscle Structure 
Skeletal muscle is made up of different types of myofibers. The two main 
types are the slow-twitch oxidative fiber, Type I, and the fast-twitch glycolytic 
fibers, Type IIa, IIx, IIb and IIc (7, 14, 61).  Each fiber type has different metabolic 
properties.  Type I fibers, for example, have been shown to contain a high 
amount of intramuscular lipids, not seen in type II fibers (20, 28, 36, 42). Type I 
fibers, which use primarily aerobic metabolism, are better equipped to use lipids 
as fuel.  It has been shown that the amount of weight loss and reduction in BMI 
following gastric bypass surgery in morbidly obese subjects was related with the 
amount of type I fibers each subject had (82).   
 
It has been shown in rats, mice, and humans that there is a significant 
decrease in the amount of type I fibers associated with obesity (27, 29, 31, 36, 
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38, 83, 88).  Likewise, there is a significant increase in type II fibers with obesity 
(36, 38, 83), particularly type IIb fibers (36, 83).  Along with this fiber type shift 
there has been found to be an increase in the amount of hybrid fibers in the 
sternomastoid, EDL, and the soleus in ob/ob mice compared to lean cohorts (38).  
This shift corresponds with the increase in functional demand on the postural 
muscles that are now being required to support a larger body mass, locomotor 
muscles that are overcoming greater inertia in order to move, and an increase in 
the effort behind ventilation (38).   
 
Protein Synthesis and Translation Initiation 
Obesity by itself can cause complications with protein synthesis.  Mice that 
were made obese by goldthioglucose injection showed less adaptive growth 
following an exercise regime (3).  When compared to lean controls, these obese 
mice showed only a 2x increase in protein turnover whereas lean mice show a 3x 
increase (3). Protein content is also lower in the muscles of the obese mice 
compared to lean cohorts (3).  There is data suggesting that altered protein 
synthesis in the obese is slower in slow (type I) muscle more so than fast (type II) 
muscle fibers.  Protein turnover has been shown to be slowest and total RNA 
content lower in type I fibers of the vastus lateralis fibers of dogs, mice, rats, and 
fowl (75).  
 
 Muscle growth is dependent upon the synthesis of proteins through the 
initiation of polypeptide chains. Protein synthesis within skeletal muscle is 
controlled by hormonal and nutritional factors as well as the body’s supply of 
amino acids, insulin and other initiation factors, RNA, and met-tRNA (64).  Insulin 
does not necessarily stimulate protein synthesis but rather facilitates synthesis by 
stimulating downstream machinery (79).  For example, for the initiation of 
peptide-chains to take place within eukaryotic cells there must be an mRNA 
dependent binding of the 40S and 60S ribosomal subunits creating an 80S 
monomer (64).  The binding of mRNA to the 40S ribosomal subunit involves the 
binding of eIF-4E (eukaryotic initiation factor – 4E) to the m7GTP cap at the 
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5’end of the mRNA. The newly formed eIF-4E – mRNA complex binds to another 
initiation factor, eIF-4G, which contains binding sites for the other initiation 
factors, eIF-4A and eIF-3.  This complex then binds to the 40S ribosomal subunit 
(78).  Phosphorylation of 4E-BP1 is caused by insulin and IGF-1 (79).  4E-BP1 
also regulates 40S ribosome binding to mRNA, though indirectly, by increasing 
the availability of eIF-4E (78). When eIF-4E is bound to 4E-BP1 it can bind to 
mRNA through the m7GTP cap but not to eIF-4G. But when 4E-BP1 is 
phosphorylated it releases eIF-4E allowing it to bind with eIF-4G and 
subsequently to the 40S ribosomal subunit (78).  
 
 Impaired insulin and IGF-1 action, like in obesity and diabetes, leads to 
atrophy of skeletal muscle due to its inability to synthesize proteins (37, 57).  In 
the db/db diabetic mouse model, there is a 48% decrease in protein synthesis 
when compared to lean controls (72).  The accompanying decrease in RNA 
negatively affects translational efficiency not allowing the formation of new 
peptide chains (64).  RNA concentrations in gastrocnemius muscles of male 
Sprague-Dawley rats were 13% lower after just two days in a simulated diabetic 
state (25).  Since approximately 80% of RNA is rRNA, any decreases in RNA will 
blunt protein synthesis (25). 
 
Amino Acids 
 Part of the action of insulin on protein synthesis is its effects on stimulating 
the incorporation of amino acids into proteins (78).  Increases in the amounts of 
circulating amino acids are observed in obesity (57).  Branched chain amino 
acids have been shown to affect carbohydrate metabolism by decreasing the 
glucose used within skeletal muscle (60).  In obese humans, eight amino acids 
have been shown to be significantly increased (alanine, valine, 
leucine/isoleucine, phenylalanine, tyrosine, glutamate/glutamine, 
aspartate/asparagines, and arginine) compared to lean cohorts (57).  This could 
cause a build up in these amino acids because they compete for transport with 
the large neutral amino acid transporter, LAT1, resulting in the reduced 
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production of neurotransmitters (i.e. serotonin) and catecholamines within the 
central nervous system (57). Since IGF-1 is decreased in obesity, combined with 
overnutrition, the larger amounts of circulating amino acids will be diverted into 
catabolic pathways instead of being used for protein synthesis. For example, 
glutamate increases in α-ketoacids, C5, and C3 acylcarnitines.  C5 acylcarnitines 
are comprised of subunits that lead to mitochondrial isoleucine and leucine 
catabolism (57). High glutamate could also increase transamination of pyruvate 
to alanine (both found to be increased in obesity), which could lead to glucose 
intolerance in obesity (57).  
 
Growth Signaling 
Mammalian Target of Rapamycin (mTOR) 
 Rapamycin is used in clinical applications, such as organ transplants and 
cancer treatment, because of its immunosuppressive action that negatively 
affects proliferation.  The molecular target of rapamycin is a Ser/Thr kinase called 
mTOR in mammals (86).  mTOR is a part of the phosphatidyl-inositol 3 kinase 
(PI3K) family of enzymes (67).  mTOR is associated with sensing nutrient 
availability, adjustment of insulin action in vivo, increases in muscle mass via an 
increase in RNA translation and protein synthesis, the balance of ATP 
production, and regulating mitochondrial function (4, 5, 44, 71, 92).  mTOR is 
comprised of two separate multiprotein complexes, mTOR Complex 1 (TORC1) 
and mTOR Complex 2 (TORC2) (34, 69).   TORC1 consists of the regulatory 
protein of mTOR, raptor, which is rapamycin-sensitive (4, 41).  Raptor interacts 
with IRS-1 to regulate the phosphorylation of IRS-1 at Ser-636/639 by mTOR 
(89).  TORC1 controls the phosphorylation of downstream targets 4E-BP1 and 
ribosomal protein S6 kinase-1 (S6K1) (16). When mTOR phosphorylates 4E-
BP1, eIF-4E is free to bind with other initiation factors and the 40S ribosomal 
subunit, allowing translation initiation to occur.  S6K1 activation causes feedback 
inhibition of the insulin/IGF1 pathway by decreasing the levels and 
phosphorylation of IRS-1 (26, 90).  However, this effect on IRS-1 phosphorylation 
is not direct. This is done through another negative feedback regulation of PI3-
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kinase/Akt signaling by phosphorylating rapamycin-sensitive residues such as 
Ser307 (89). Another protein in TORC1 is mLST8, which interacts directly with 
mTOR and positively regulates its ability to phosphorylate S6K1 (89). 
 
In muscle cells glucose uptake is controlled through activation of the PI3-
kinase/Akt pathway, which is stimulated by insulin (59).  When TORC1 is 
activated for prolonged periods of time, as is the case in nutrient excess, insulin 
resistance results due to decreased signal transduction of insulin at the level of 
IRS-1 (54, 67, 85).  Consequently, ribosomes released following peptide-chain 
termination accumulate as 80S monomers, not as 40S and 60S subunits (37).  
This has detrimental effects on translation initiation. Insulin resistance associated 
with increased TORC1 is evidenced in the ob/ob mouse, which has constantly 
activated TORC1 associated with increases in basal PKB/Akt activity (54).   
 
 Raptor knock out mice (RAmKO) show significant decreases in S6K1 and 
4E-BP1 phosphorylation and display progressive muscular dystrophy (4).  
Glycogen content is increased in the EDL, soleus, and gastrocnemius muscles of 
these animals (4).  EDL and soleus muscles in RAmKO mice also display 
significant decreases in oxidative enzymes, intermyofibrillar mitochondria, and 
glucose uptake from the blood (4).  This provides further evidence of the role of 
the complex in controlling muscle mass, oxidative metabolism, and insulin action. 
 
TORC2 consists of Rictor, which is the rapamycin-insensitive component 
of mTOR (4).  TORC2 controls the phosphorylation of PKB/Akt at Ser473 (70). 
PKB/Akt acts as a feedback regulator of TORC1 activation (6) and is acted on by 
S6K1 to regulate IRS-1 phosphorylation through negative feedback (89).  
PKB/Akt increases TORC1 by phosphorylating TSC 1 and 2 (54).  This enhances 
GTP loading to Rheb, an mTOR interacting protein that is essential for mTOR 
activity (54).  In order for phosphorylation of Akt at Ser 473 to take place the 
rictor interacting protein mSin1 is required (89).  A downstream target of PKB/Akt 
is glycogen synthase kinase 3α/β (GSK3α/β).  The β isoform of GSK3 has been 
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shown to be the major enzyme that inhibits glycogen synthase (33, 52).  When 
phosphorylated by Akt, GSK3β is inhibited, increasing glycogen synthase activity 
(52). 
 
The rictor knock out mouse (RImKO) appears normal and does not die 
prematurely like RAmKO mice (4).  There is no change in the structural makeup 
of the EDL and Soleus muscles that is responsible for the absence of muscular 
dystrophy (4).  Interestingly, there is a slight decrease in the amount of raptor in 
the RImKO mice (4). PKB/Akt on Ser 473 is still phosphorylated, meaning that 
mTORC2 is not required for its phosphorylation (4) but apparently it plays a role 
in the degree of raptor expression. 
 
AMPK 
AMPK operates in response to stress as a cellular fuel sensor particularly 
as a result of the AMP:ATP ratio (12, 24). AMPK is a ubiquitous Ser/Thr kinase 
heterotrimer made up of a catalytic α subunit as well as β and γ regulatory 
components that complete the complex (35, 48).  The most common causes of 
AMPK activation are hypoglycemia, exercise, and fasting (35).  When activated, 
it initiates the production of ATP while inhibiting pathways that consume it (48).  
In skeletal muscle, AMPK regulates glucose metabolism and gluconeogenesis 
(66). It also controls fatty acid oxidation by phosphorylating acetyl-CoA 
carboxylase 2 (ACC2) (66).  Situations where lipid metabolism is impaired, as in 
obesity, could be a result of a dysregulation in the fuel sensing ability of AMPK 
(35).  If fatty acids cannot be oxidized within the mitochondria they will be 
synthesized into DAG, ceramides, and TG within the cytosol causing inhibition of 
the insulin pathway decreasing glucose uptake (35). 3-guanidinopropionic acid 
(β-GPA) is a known AMPK activator by competing against phosphocreatine and 
not allowing it to enter into the muscle and subsequently lowing ATP levels (18, 
19, 73).  β-GPA has been shown to induce hypoglycemia in non-diabetic rabbits 
(1).  Its effects on reducing glucose and insulin levels as well as increasing 
insulin sensitivity have been seen in ob/ob mice (53).  5’-aminoimidazole-4-
 
  
 13 
carboxamide-1-β-D-ribofuranoside (AICAR) is another known AMPK activator 
(10, 12, 67).  AICAR acts as an intermediate in the generation of inosine 
monophosphate (IMP), an AMPK agonist, thus increasing activity of AMPK (10, 
12, 67).  Exercise also affects AMPK by depleting ATP and increasing amounts 
of AMP.  This change in the AMP:ATP ratio increases AMPK activity.   
 
AMPK’s control of mTOR 
AMPK controls translation and growth via an mTOR dependent 
mechanism.  Increases in AMP activate AMPK by phosphorylating the Thr 172 
residue on the catalytic α subunit (35).  AMPK in turn causes the phosphorylation 
and subsequent inactivation of acetyl-CoA carboxylase (ACC), the rate-limiting 
enzyme in fatty acid oxidation (83).  ACC has two isoforms, ACC1 and ACC2, 
with ACC2 being the predominant isoform within skeletal muscle.  AMPK 
phosphorylates ACC1 on Ser 79 and ACC2 on the equivalent Ser 221 repressing 
the mTOR pathway (23, 83).  This decreases fatty acid production as well as up-
regulates fatty acid oxidation and mitochondrial biogenesis by increasing citrate 
synthase and succinate dehydrogenase (23, 35, 66, 67, 77).    
 
AMPK phosphorylates the tuberous sclerosis complex 2 gene product, 
Tuberin or TSC2 (92).  TSC2, whose function is inhibited upstream by Akt, 
functions as a GTPase-activating protein (GAP) to the Rheb G protein, an 
upstream target of mTOR (13). Rheb is then converted to its inactive GDP form 
that decreases mTOR activity (13).  Therefore, AMPK also acts indirectly to 
inhibit mTOR signaling through TSC2. 
 
Fatty Acids 
 Chronic exposure to lipids increases mTORC 1 and 2 formation (67).  
Increases in mTORC1 were indicated by increased activation of S6K1 at Thr 389 
(67). This increased the serine phosphorylation of IRS-1 (67).  mTORC2 
formation was coupled with increases in Akt at Ser 473 (67).  Increases in fatty 
acids have also been associated with suppressed AMPK signaling (76).     
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Significance 
  Considering the rising prevalence of obesity among the population of this 
country, understanding the effects that obesity has on skeletal muscle mass will 
be crucial for combating this problem.  Because of the role skeletal muscle plays 
in substrate utilization, basal metabolic rate, functionality, and personal 
independence, any detriments in size and function of the muscle has significant 
impacts on both quality of life and the financial burden of health care.  As our 
obese population grows older, there will be factors contributing that are 
detrimental to skeletal muscle.  Having an understanding of skeletal muscle 
mass in the role of obesity alone plays will improve care in individuals.  Findings 
from this study will point towards new ways to treat and prevent the problem of 
obesity, thus improving the quality of life in these individuals. 
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Chapter 3:  Methods 
Aim #1: Determine the role of AMPK activation on skeletal muscle mass 
and morphology within obese muscle. 
Design 
The experimental groups consisted of 8 C57BL/6 (lean) mice and 8 ob/ob 
mice fed either a 1% β-GPA containing diet, or 8 lean and ob/ob mice fed normal 
chow.  Ob/ob mice are a rodent model of obesity and hyperlipidemia.  These 
mice spontaneously develop a mutation of the leptin gene and subsequently 
develop high circulating levels of triglycerides, total cholesterol, and low density 
lipoproteins (15, 32).  The ob/ob mouse also displays characteristics of type 2 
diabetes in that hyperinsulinemia, hyperglycemia, insulin resistance, hyper-
aminoacidemia, and intolerance to glucose are all present (9, 15, 49-51).  Few 
studies have examined skeletal muscle growth regulation in these animals or 
how to attenuate their muscle loss.  The data show lower activation of the insulin 
stimulated PI 3-kinase/Akt growth pathway and that mTOR signaling is highly 
active in these animals (54, 98).  This makes them a good experimental model to 
gain insight into the intricacies of how these pathways control muscular growth 
during obesity but also to discover an efficient means by which to treat these 
pathologies.  
 
Feeding with 1% β-GPA is being used as a means to increase AMPK 
activation. This quantity of β-GPA was chosen based on the viability and 
response of the animals in previous experiments using the same diet (17-19, 73).  
Body weight and food intake were recorded twice a week for the duration of the 
8-week feeding. The experimental period is ample time to observe changes in 
skeletal muscle mass relative to body weight and tibial length (75, 87). The 
average weight of the mice in each cage as well as food intake was calculated 
each week.  Following a 12 hr fast, muscle was collected while the animal was 
anesthetized. Gastrocnemius complexes were weighed then immediately frozen 
in liquid nitrogen. Tibial lengths were measured as another means to normalize 
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muscle growth.  We measured the ATP in muscle and examined AMPK 
activation as validation of the treatment. 
 
Aim #2: Determine how obesity alters mTOR-related signaling in skeletal 
muscle and evaluate the benefit of AMPK activation. 
Design 
The experimental groups consisted of 8 C57BL/6 (lean) mice, 8 ob/ob 
mice fed a 1% β-GPA containing diet, and 8 lean and ob/ob mice fed normal 
chow.  1% β-GPA was used as a means to increase AMPK activation and 
repress mTOR signaling. This quantity of β-GPA is based on the viability and 
response of animals in previous experiments using the same diet (17-19, 73).  
The goal was to identify the regulatory pathway through which AMPK activation 
attenuates obesity-induced muscle atrophy.  The experimental period was ample 
time to observe changes in skeletal muscle mass relative to body weight and 
tibial length.  Body weight and food intake were measured 2x week throughout 
the feeding period.  After the proposed period, muscle samples were collected 
while the animal is under anesthesia.  The gastrocnemius complex was analyzed 
by immunoprecipitation and Western Blot for mTOR and mTOR-related activation 
and association. 
 
General Methodologies 
Animals – Lean and ob/ob (Catalog #000632) male mice from Jackson 
Laboratories in Bar Harbor, ME were used for the proposed experiments. All 
animals were maintained on a 12:12, light:dark cycle and controls were fed 
standard chow (Harlan; #2018) while the experimental groups are fed β-GPA 
(Sigma-Aldrich; #G 6878) mixed with standard chow (Harlan; #2018).  The 
experimental diet was prepared by Harlan.  The experimental groups consisted 
of 8 C57BL/6 (lean) mice fed β-GPA, 8 ob/ob mice fed β-GPA, and 8 lean and 
ob/ob mice fed normal chow.  Food and water was available ad libitum. After the 
proposed time and following an overnight fast, samples were collected while the 
animal was anesthetized by 4% isoflurane.  Body weight was measured while the 
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animal was anesthetized.  Gastrocnemius complexes were removed and 
weighed then immediately frozen in liquid nitrogen for later analysis. The right 
tibia was removed and immediately placed in a -20°C freezer until the length 
could be measured. 
 
β-GPA – 3-guanidinopropionic acid was mixed with normal chow from Harlan to 
make a 1% β-GPA mixture (17-19, 73).  Body weight was measured every 3rd 
day (2x week).  Food intake was measured at those times to track food 
consumption. The average weight and food intake, per mouse of each cage was 
calculated at the end of each week to track body weight gain and food 
consumption. 
 
Muscle Size – The gastrocnemius complex (soleus, plantaris, and the two heads 
of the gastroc) was surgically dissected tendon-to-tendon and any fat around the 
tissue was removed before the muscle was weighed. Because of the likelihood 
that body mass change is accompanied by a change in muscle mass, muscle 
mass was normalized to body weight, skeletal muscle protein concentration, and 
tibia length. 
 
ATP Determination –Invitrogen Detection Technologies ATP Determination Kit 
(A22066) was used.  This is a bioluminescence assay for quantitative 
determination of ATP with recombinant firefly luciferase and its substrate D-
luciferin.  Amount of ATP was calculated in the experimental samples from a 
provided standard curve. 
 
Homogenizing of Muscle – Muscle tissue was homogenized in 10x homogenizing 
buffer.  Homogenizing buffer consisted of 10 µl/ml protease inhibitor, 1 µl/ml 
DTT, 5 µl/ml Benzamidine, 2.5 µl/ml Sodium Vanadate, and the rest was made 
up of CHAPS buffer.  A 50 µl aliquot of the total homogenate was placed in a 
separate tube with 50 µl of sample buffer for totally lysate analysis. The 
remaining homogenates were spun at 1000xG for 10 min @ 4 °C.  The 
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supernatant was taken and placed in separate tubes and the remaining pellet will 
be discarded.  An aliquot of 10 µl was taken of the samples for a protein assay 
while the rest was stored in an -80 °C freezer.   
 
Protein Determination – Bovine serum albumin was used to determine protein 
concentration of the muscle samples using the Coommassie Stain Assay 
(Thermo Scientific).  The plate was run through the plate reader (595 nm) to 
calculate protein concentration.  A workable dilution was calculated for each 
sample that was used in subsequent Western Blot analysis. 
 
Immunoprecipitation – The sample was processed in CHAPS buffer and 500 µg 
of 1000xg supernatant was combined with eIF-4E or mTOR antibody and mixed 
overnight.  Immune complexes were isolated with a goat anti-rabbit or –mouse 
BioMag IgG beads (Qaigen), using a magnetic stand.  Precipitates were eluted in 
SDS sample buffer, boiled, pelleted by magnet, collected, and subjected to 
standard Western analysis for eIF-4E, eIF-4G, and 4E-BP1 (eIF-4E IPs only) or 
mTOR and raptor (mTOR IPs only). mTOR’s association with raptor was 
analyzed from mTOR immunoprecipitates, and eIF-4E and 4E-BP1 associated 
with eIF-4E was examined in eIF-4E immunoprecipitates.  
 
Western Analysis – Degree of activation of AMPK, mTOR and their substrates 
raptor, S6K1 (total and phospho), 4E-BP1 (total and phospho), rpS6, eEF-2, 
GSK3-α/β, p-Akt (Ser 473 and Thr 308), total Akt, and ACC were analyzed by 
Western analysis from skeletal muscle homogenates.  Results were normalized 
to β-Tubulin.  TOR, raptor, S6K1 (total/phospho), GSK3α/β, and ACC were run 
on a 7% gel.  BP1 (total/phospho), eEF-2, and p-Akt (Ser473/Thr 308), and total 
Akt were run on a 4-12% gel. AMPK (phospho), PGC-1α, COXIV, β-Tubulin, and 
rpS6 (phospho) were run on a 12% gel.  Equal protein was resolved by SDS-
PAGE (NuPAGE; Invitrogen). A kaleidoscope marker was used to visually 
determine protein placement based on weight (kDa).  Gels ran for ~90 minutes at 
125 V in cold room until samples have run the length of the gel. They were 
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transferred to PVDF membrane for 75 min at 30 V. The resulting membranes 
were blocked in 5% milk (5 grams dehydrated milk/100 ml TBST) for 60 min at 
room temperature. Membranes were rinsed 4x10 minutes with 1x TBST and then 
incubated with the appropriate primary antibody diluted in 1x TBST overnight in 
cold room.  The next day membranes were rinsed 3x5min with 1x TBST then 
rocked in their respective HRP-conjugated-secondary antibodies diluted in 5% 
milk in TBST.  All primary and secondary antibodies were purchased through Cell 
Signaling Technology Inc.  Immunoblots were visualized via ECL or ECL-
Advanced and captured by a camera-integrated system (SynGene). 
Concentration of protein expression was assessed by ImageJ software.  Results 
will then be compared to percent of the control.   
 
Statistics 
All data are expressed as mean±standard error of the mean.  Comparisons are 
made to the lean controls, using a one- or two-way (body weight and food intake 
only) ANOVA analysis (Prism v3.0 software; GraphPad Software). The 
significance level is P<0.05. 
 
  
 20 
Chapter 4: Manuscript in JAP style 
Abstract 
The aim of this study was to identify obesity-induced alterations in regulatory 
mechanisms of skeletal muscle mass and how they would be altered with long 
term (8 weeks) AMPK-agonist treatment.  8 week old male, lean (L) wild type 
[body weight (BW) = 26.9 g] and ob/ob (O) [BW = 46.2 g] mice were fed an AMP 
kinase (AMPK) activator, β-GPA (F), mixed at a 1% concentration within their 
food or normal chow as control (C) for 8 weeks.  Following an overnight (12 hr) 
fast, all mice were sacrificed and the gastrocnemius complex was excised for 
analysis.  Muscle mass was lower in the OC mice (121.08 ± 9.3 mg) versus LC 
(158.4 ± 5.6 mg).  This corresponded with decreases in raptor associated with 
mTOR. Following treatment, western analysis of OF muscle lysates displayed 
increased AMPK and acetyl-CoA carboxylase phosphorylation compared with LC 
and OC mice.  OC mice displayed higher activation of mammalian Target of 
Rapamycin (mTOR)-regulated signaling (S6K1, 4E-BP1, and GSK3), which was 
reciprocally altered after 8 weeks of β-GPA feeding.  These data show that long 
term (8 week) AMPK-agonist treatment can augment obesity-induced alterations 
in regulatory mechanisms of skeletal muscle mass through the normalization to 
lean levels of mTOR signaling. 
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Introduction 
Many of the health problems associated with obesity like lipotoxicity, 
dyslipidemia, type 2 diabetes and chronic inflammation have significant impacts 
on skeletal muscle function.  This decrease in function is due to muscle atrophy 
as seen in both humans and animals (38, 39, 54, 57).  Obese humans have been 
shown to have as much as twice the amount of fat mass as their lean 
counterparts but only 17% more lean mass (58).  This corresponds to only 60% 
of the body weight in obese subjects coming from skeletal muscle compared to 
71% in lean counterparts (58).  
 
Loss in muscle mass is caused by an imbalance between the protein 
synthesis and degradation rates (3).  Synthesis of protein relies upon ribosomal 
mRNA translation that is controlled by the molecular target of rapamycin in 
mammals, or mTOR (5, 92).  Acute increases in mTOR result in muscle 
hypertrophy and growth but chronically elevated mTOR signaling, as seen in 
obese muscle, may negatively impact growth (40, 54, 90). 
 
mTOR is comprised of two separate multi-protein complexes, mTOR 
complex 1 and 2, that contain the regulatory proteins raptor and rictor, 
respectively (4, 35, 42, 70).  Raptor phosphorylates the eukaryotic initiation factor 
(eIF) 4E binding protein-1 (4E-BP1) and ribosomal protein S6 Kinase-1 (S6K1) 
(8).  In its unphosphorylated state, 4E-BP1 binds to eIF-4E, a key initiation factor 
in translation, which keeps other initiation factors from binding. Under normal 
conditions 4E-BP1 is phosphorylated by raptor, which then releases eIF-4E, 
allowing it to bind to eIF-4G and MAP kinase-interacting kinase to form the eIF-
4F complex (78, 79).  The eIF-4F complex then binds with the mRNA and 40S 
ribosomal subunit so that together with a 60S subunit a functional 80S 
monosome can form (78).  S6K1 phosphorylation recruits other proteins involved 
in the translation initiation process such as eIF-4B, ribosomal protein S6 (rpS6) 
and eukaryotic elongation factor 2 kinase (eEF-2) (16, 65).    
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mTOR can be regulated by a ubiquitous Ser/Thr kinase heterotrimer, 5’ 
AMP-activated protein kinase (AMPK) (36, 53).  Increases in AMP, activates 
AMPK by phosphorylating the Thr 172 residue on the catalytic α subunit initiating 
ATP production and inhibiting pathways that consume it (36, 53). AMPK 
activation causes the phosphorylation and subsequent inactivation of acetyl-CoA 
carboxylase (ACC), the rate-limiting enzyme in fatty acid oxidation (89).  The two 
isoforms of ACC are phosphorylated by AMPK on Ser 79 (ACC1) and Ser 221 
(ACC2) repressing the mTOR pathway (23, 89).  This decreases fatty acid 
production as well as up-regulates fatty acid oxidation and mitochondrial 
biogenesis by increasing citrate synthase and succinate dehydrogenase (23, 36, 
67, 68).   AMPK also indirectly regulates mTOR by phosphorylating tuberous 
sclerosis complex 2 (TSC2) (94).  TSC2 functions as a GTPase-activating protein 
(GAP) to the Rheb G protein, an upstream target of mTOR (13). Rheb is then 
converted to its inactive GDP form, decreasing mTOR activity (13). 
 
  A state of nutrient excess, i.e. obesity, results in chronically elevated 
mTORC1 and 2 levels and ultimately insulin resistance (55, 68).  In ob/ob mice, a 
model of obesity and insulin resistance, it has been shown that there is an 
accompanied decrease in AMPK signaling (79).  However, It is unclear how 
obese skeletal muscle can display reductions in mass while having excessive 
nutrients available and increased mTOR signaling.  AMPK’s control of mTOR 
and the evidence that it is reduced in obesity make it a desirable target in which 
to treat altered mTOR signaling in obese skeletal muscle (13, 23, 83, 96).  
Therefore, our goal in this study is to evaluate the effectiveness of long-term 
AMPK agonist treatment on skeletal muscle mass during obesity.  Our 
hypothesis is that long-term (8 week) treatment with the AMPK agonist, β-GPA, 
will normalize obesity-induced increases in mTOR and mTOR-related signaling 
to lean levels, promoting proper growth of obese skeletal muscle. 
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Materials and Methods 
Materials – β-GPA (3-guanidinopropionic acid) was purchased from Sigma-
Aldrich (#G6878) and mixed with normal chow from Harlan (#2018) to make a 
1% β-GPA mixture (17-19, 73). ATP Determination Kit (A22066) was purchased 
from Invitrogen Detection Technologies.  All antibodies were purchased from Cell 
Signaling Technology.  Anti-mouse horseradish peroxidase-conjugated IgG were 
purchased from Cell Signaling Technology.  Biomag beads were purchased from 
Qaigen. 
 
Animals – Lean and ob/ob (#000632) male mice from Jackson Laboratories in 
Bar Harbor, ME were used for the proposed experiments. All animals were 
maintained on a 12:12, light:dark cycle and controls were fed standard chow 
(Harlan; #2018) while the experimental groups are fed β-GPA (Sigma-Aldrich; #G 
6878) mixed with standard chow (Harlan; #2018).  The experimental diet was 
prepared by Harlan.  The experimental groups consisted of 8 C57BL/6 (lean) 
mice fed β-GPA, 8 ob/ob mice fed β-GPA, and 8 lean and ob/ob mice fed normal 
chow.  Food and water were available ad libitum. After the proposed time and 
following an overnight fast, samples were collected while the animal was 
anesthetized by 4% isoflurane.  Body weight was measured while the animal was 
anesthetized.  Gastrocnemius complexes were removed and weighted then 
immediately frozen in liquid nitrogen for later analysis.  The right tibia was 
removed and immediately placed in a -20 °C freezer until the length could be 
measured. 
 
β-GPA – 3-guanidinopropionic acid was acquired from Sigma-Aldrich (#G 6878) 
and mixed with normal chow from Harlan (#2018) to make a 1% β-GPA mixture 
(17-19, 73).  Body weight was measured every 3rd day (2x week).  Food intake 
was measured at those times to track food consumption. The average mouse 
and food weight of each cage was calculated at the end of each week to track 
body weight gain and food consumption, repetitively. 
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Muscle Size – The gastrocnemius complex (soleus, plantaris, and the two heads 
of the gastroc) was surgically dissected tendon-to-tendon and any fat around the 
tissue was removed before the muscle was weighed. Because of the likelihood 
that body mass change is accompanied by a change in muscle mass, muscle 
mass was normalized to body weight, skeletal muscle protein concentration, and 
tibia length. 
 
ATP Determination – We used Invitrogen Detection Technologies’ ATP 
Determination Kit (A22066).  This is a bioluminescence assay for quantitative 
determination of ATP with recombinant firefly luciferase and its substrate D-
luciferin.  Amount of ATP was calculated in the experimental samples from a 
provided standard curve. 
 
Homogenizing of Muscle – At a later time muscles tissue were homogenized in 
10x homogenizing buffer.  Homogenizing buffer consisted of 10 µl/ml protease 
inhibitor, 1 µl/ml DTT, 5 µl/ml Benzamidine, 2.5 µl/ml Sodium Vanadate, and the 
rest was made up of CHAPS buffer.  A 50 µl aliquot of the total homogenate was 
placed in a separate tube with 50 µl of sample buffer for totally lysate analysis. 
The remaining homogenates were spun at 1000xG for 10min @ 4 °C.  The 
supernatant was taken and placed in separate tubes and the remaining pellet will 
be discarded.  An aliquot of 10 µl was taken of the samples for a protein assay 
while the rest was stored in an -80 °C freezer.   
 
Protein Determination – A Bovine serum albumin was used to determine protein 
concentration of the muscle samples using the Commassie Stain Assay (Thermo 
Scientific).  The plate was run through the plate reader (595 nm) to calculate 
protein concentration.  A workable dilution was calculated for each sample that 
was used in subsequent Western Blot analysis. 
 
Immunoprecipitation – The sample was processed in CHAPS buffer and 500 µg 
of 1000xg supernatant was combined with eIF-4E or mTOR antibody and mixed 
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overnight.  Immune complexes were isolated with a goat anti-rabbit or –mouse 
BioMag IgG beads (Qaigen), using a magnetic stand.  Precipitates were eluted in 
SDS sample buffer, boiled, pelleted by magnet, collected, and subjected to 
standard Western analysis for eIF-4E, eIF-4G, and 4E-BP1 (eIF-4E IPs only) or 
mTOR and raptor (mTOR IPs only). mTOR’s association with raptor was 
analyzed from mTOR immunoprecipitates, and eIF-4E and 4E-BP1 associated 
with eIF-4E was examined in eIF-4E immunoprecipitates.  
 
Western Analysis – Degree of activation of AMPK, mTOR and their substrates 
raptor, S6K1 (total and phospho), 4E-BP1 (total and phospho), rpS6, eEF-2, 
GSK3-α/β, p-Akt (Ser 473 and Thr 308), total Akt, and ACC were analyzed by 
Western analysis from skeletal muscle homogenates.  Results were normalized 
to β-Tubulin.  TOR, raptor, S6K1 (total/phospho), GSK3α/β, and ACC were run 
on a 7% gel.  BP1 (total/phospho), eEF-2, and p-Akt (Ser473/Thr 308), and total 
Akt were run on a 4-12% gel. AMPK (phospho), PGC-1α, COXIV, β-Tubulin, and 
rpS6 (phospho) were run on a 12% gel.  Equal protein was resolved by SDS-
PAGE (NuPAGE; Invitrogen). A kaleidoscope marker was used to visually 
determine protein placement based on weight (kDa).  Gels ran for ~90 minutes at 
125 V in cold room until samples have run the length of the gel. They were 
transferred to PVDF membrane for 75 minutes at 30 V. The resulting membranes 
were blocked in 5% milk (5 grams dehydrated milk/100 ml TBST) for 60 min at 
room temperature. Membranes were rinsed 4x10 minutes with 1x TBST, then 
incubated with the appropriate primary antibody diluted in 1x TBST over night in 
cold room.  The next day membranes were rinsed 3x5 min with 1x TBST then 
rocked in their respective HRP-conjugated-secondary antibodies diluted in 5% 
milk in TBST.  All primary and secondary antibodies were purchased through Cell 
Signaling Technology Inc.  Immunoblots were visualized via ECL or ECL-
Advanced and captured by a camera-integrated system (SynGene). 
Concentration of protein expression was assessed by ImageJ software.  Results 
will then be compared to percent of the control.   
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Statistics 
All data are expressed as mean±standard error of the mean.  Comparisons are 
made to the lean controls, using a one- or two-way (body weight and food intake 
only) ANOVA analysis (Prism v3.0 software; GraphPad Software). The 
significance level is P<0.05. 
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Results 
mTOR Signaling Activation in Ob/ob Mouse Skeletal Muscle. Previous studies 
(40, 54, 90) have reported that obese mouse models have elevated mTOR 
signaling under fasted conditions.  In support of our model, we examined mTOR 
signaling activation of TORC1 substrates S6K1 and rpS6 in various skeletal 
muscles of the lower limb from both lean and ob/ob mice (Fig 1).  We examined 
predominantly mixed, slow, and fast contractile-type muscles (gastrocnemius, 
soleus, and tibialis anterior respectively).  All three muscles types displayed 
elevated mTOR signaling under fasted conditions compared to muscles from 
lean counterparts. 
 
AMPK and ACC Phosphorylation.  Following a 12 hr fast, activation of AMP 
Kinase (AMPK), on the phosphorylation site T172 and its substrate acetyl-CoA 
carboxylase (ACC) on the S79 phosphorylation site was determined by western 
blot analysis to verify the efficacy of the obese model and the treatment with the 
AMPK agonist β-GPA.  Unlike previous investigations, including our own, there 
was no statistically significant difference between the levels of AMPK T172 and 
ACC S79 phosphorylation in OC mice to LC mice (Fig 2a).  Following 8 weeks of 
feeding with β-GPA mixed chow and a 12hr fast, the fasted obese skeletal 
muscle AMPK phosphorylation increased significantly above those of the LC 
mice.  ACC phosphorylation levels significantly increased compared to the OC 
mice (Fig 2a). 
 
ATP.  ATP was found to be significantly less in the skeletal muscle of both lean 
and ob/ob groups fed 1% β-GPA, compared to their respective control groups 
(Fig 2b).  Since β-GPA is a known creatine kinase competitor, driving down ATP 
levels, this data is a positive indicator, along with increased AMPK (p), of the 
efficacy of our treatment. 
 
Body Mass and Food Intake Between Groups.  Body mass was measured in 
each mouse 2x a week.  Comparisons were made using a Two Way ANOVA 
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analysis.  LF and OC mice displayed significant differences in body mass 
throughout the 8 weeks of feeding with the means for LF and OC mice being 
42.1% lighter and 86.3% heavier, respectively, than that of LC mice (Table 1).  
The OF mice decreased in weight to the point of there being no significant 
difference to the weight of the LC mice during week 4 (Fig 3).  This reduction in 
weight remained until week 6 where the OF mice started to regain weight (~5 g). 
However, despite this gain they remained 29.0% lighter than the OC mice and 
only 32.3% heavier than LC mice (Table 1) after 8 weeks on the 1% β-GPA. 
Food intake between groups also increased in the LC, LF, and OC groups (Fig 
4).  The OF group ate the least for the first 4 weeks then their intake increased to 
where it was similar with LC mice by 8 weeks.  This corresponds with the OF 
mice having no significant difference in body weight to the LC mice during weeks 
4-6 then significantly increased weight gain for the last 2 weeks of the study. 
 
Gastrocnemius Complex Muscle Characteristics.  The gastrocnemius complex 
(including the soleus, plantaris, and the medial and lateral heads of the 
gastrocnemius muscles) skeletal muscle weight was significantly lower in the OC 
mice compared to the LC group (Table 1).  We then compared muscle weight 
relative to body mass and found that this resulted in a ratio that was 59.0% lower 
than that of LC (Table 1).   After 8 weeks of β-GPA feeding, the OF group’s 
gastrocnemius complex muscle weight was 43.3% lower than that of the LC mice 
(Table 1) and significantly less than OC (Table 1).  However, relative to body 
mass, this resulted in an increase of 5.3% over OC mice (Table 1). 
 
 Tibial length was measured in each group.  Though statistical significance 
was found in both treated groups, it should be noted that there is very little 
variance between groups (Table 1).  One mouse in the OF group was excluded 
from analysis because the tibia was more than two standard deviations away 
from the mean.  When comparing muscle weight to tibial length the ratio between 
the LF and OF groups was 39.8% and 23.5% lower than LC mice, respectively 
(Table 1). 
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PGC-1α and COX IV.  Western analysis of total muscle lysates for PGC-1α 
protein expression, a strong indicator of oxidative metabolism, showed no 
difference between lean and ob/ob control mice (Fig 5a).  Following 8 weeks of 
1% β-GPA feeding there was no change in either lean or ob/ob mice(Fig 5a).  
COXIV, an indicator of mitochondrial function, was analyzed via western analysis 
of total muscle lysates.  Again, no difference was found between lean and ob/ob 
control mice or experimental groups (Fig 5b).  
 
Translational Initiation Complex.  Proper formation of the translation initiation 
complex is crucial for accruing of muscle mass.  Therefore, after 8 weeks of 1% 
β-GPA fed conditions, translation initiation complex (i.e. eIF-4F) formation was 
examined in eIF-4E immunoprecipitates from lean and obese (ob/ob) 
gastrocnemius complex muscle lysates.  eIF-4G association with eIF-4E showed 
no difference between lean and ob/ob mice regardless of treatment (Fig 6).  Total 
4E-BP1 associated with eIF-4E showed an increasing trend with 1% β-GPA 
feeding in both lean and ob/ob mice but statistical significance was not reached 
in either group (Fig 6). 
 
TORC1 Signaling.  The mammalian Target of Rapamycin (mTOR) protein is a 
major regulator of cell size by complexing and activating several components of 
mRNA translation initiation and elongation.  TORC1 complex of mTOR contains 
the rapamycin-sensitive protein raptor, which binds to mTOR  to activate TORC1 
substrates.  After 8 weeks of β-GPA fed conditions, raptor was examined in 
mTOR immunoprecipitates from lean and obese (ob/ob) gastrocnemius complex 
muscles.  Raptor associated with mTOR was lower in OC mice compared to LC 
(Fig 7). 
 
 Analysis of TORC1 downstream targets 4E-BP1, S6K1, and its substrate 
ribosomal protein S6 (rpS6) was also conducted by western blot in total cell 
lysates.  Following 8 week β-GPA feeding and under fasted conditions, the 
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activation of the eIF4E binding protein, 4E-BP1, was significantly higher in the LF 
and OF groups compared to Lean mice (Fig 8a).  Total 4E-BP1 showed the 
same trend though there was no statistical significance found. 
 
The T389 phosphorylation site of S6K1 was lower in OF mice versus OC 
mice returning its activation to lean levels (Fig 8b).  No significant difference was 
found in total S6K1 or rpS6 on the S240/244 phosphorylation site.  A substrate of 
S6K1, eukaryotic elongation factor (eEF) 2, regulates elongation during mRNA 
translation.  We analyzed eEF-2 on the T56 phosphorylation site where it was 
found to not differ between LC and OC groups (Fig 8c). 
 
TORC2 Signaling.  PKB, otherwise known as Akt, is a downstream target of the 
rapamycin insensitive component of mTOR, rictor, at the S473 phosphorylation 
site. After 8 weeks of β-GPA fed conditions, total Akt and the phosphorylation 
sites, T308 and S473 were found to be not significantly different between groups 
in fasted skeletal muscle (Fig 9a).  A downstream target of Akt, GSK3, is 
inhibited by Akt phosphorylation.  GSK3-β isoform is responsible for inhibiting 
glycogen synthase (53).  GSK3-β was analyzed in fasted skeletal muscle after 8 
weeks of β-GPA fed conditions. GSK3-β phosphorylation was found to be 
significantly decreased in the OF group compared to OC (Fig 9b).  
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Discussion 
 Many of the health problems associated with obesity, such as, lipotoxicity, 
dyslipidemia, type 2 diabetes, and chronic inflammation, have significant 
negative impacts on skeletal muscle function.  This decrease in function is due to 
muscle atrophy induced by obesity (54).  Loss of muscle mass is a result of an 
imbalance between the rates of protein synthesis and degradation (3).  The 
mammalian Target of Rapamycin, mTOR responds in the presence of adequate 
nutrients to increase RNA translation and protein synthesis, initiating the growth 
process (4, 5, 41, 68, 84).  However, in obesity, despite excess nutrients and 
elevated mTOR signaling, atrophy remains (6, 27, 38, 63, 67, 72).  Therefore, the 
goal of this study was to determine if continuous, long term (8 week) feeding with 
chow mixed with the AMPK agonist-mTOR antagonist, β-GPA, would normalize 
mTOR signaling and mTOR-related processes (i.e. growth) in obese mouse 
skeletal muscle to that of lean mice.  The results of the present study show that 
long term β-GPA feeding to ob/ob mice can normalize aspects of hyperactive 
mTOR-related signaling.  This attenuation of mTOR signaling following the 8 
week feeding in the obese skeletal muscle can account for some of the 
improvement seen in gastrocnemius muscle and total body mass.  Therefore, 
these data show that feeding ob/ob mice a 1% β-GPA mixed diet (AMPK agonist) 
for 8 weeks helps normalize regulatory processes controlling muscle mass.  Thus 
creating a more positive anabolic environment for the muscle that is sensitive 
and capable to growth stimuli. 
 
 Our aim in using the well established AMPK agonist, β-GPA, was to 
counter the harmful side effects that obesity has on skeletal muscle.  Skeletal 
muscle that displays dyslipidemia, type 2 diabetes, and/or obesity has been 
shown to be less responsive to growth stimuli (40, 54, 90). β-GPA decreases 
muscle creatine levels (17, 73) by acting as a competitor.  ATP is then broken 
down creating higher levels of AMP, subsequently increasing AMPK activation 
(17, 95).  Correspondingly, in the current study, 8 weeks of β-GPA feeding 
increased AMPK (p) T172 and its substrate, ACC (p) T79, in lean and ob/ob mice 
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(Fig 2). Therefore, β-GPA feeding is an effective means by which to improve 
obese skeletal metabolism and growth related signaling.  Though previously 
known to be an AMPK agonist (17-19, 73, 95), to our knowledge this is the first 
study to use β-GPA to promote growth in obese skeletal muscle.  
 
 Reduced skeletal muscle size has been associated with obesity in animals 
(38, 39) and humans (57), despite an up-regulation of the growth-promoting 
mTOR pathway (6, 27, 38, 63, 67, 72), which these data corroborate (Table 1 
and Fig 8 & 9). However, skeletal muscle mass in relation with body mass 
increased in the β-GPA fed ob/ob mice by 5.7% (versus ob/ob control mice), 
however, this change did not reach significance (Table 1).  Given that the half-life 
of mixed mouse muscle is ~21 days (75, 87) and the dramatic reductions in body 
mass that were observed in the β-GPA fed ob/ob mice over the 8 week feeding 
period (Table 1), a greater increase in muscle mass was anticipated.  Ob/ob mice 
fed β-GPA did not differ significantly in body weight from lean control mice 
between 4-6 weeks of feeding (Table 1).  After which, their food intake increased 
and they began to regain weight (Table 1).  It is possible that had we examined 
muscle weight between 4-6 weeks as opposed to 8 weeks, we would have seen 
a larger muscle mass to body mass ratio.  
 
 Previous research in obese skeletal muscle has focused on understanding 
the metabolic state of the muscle, such as hyperinsulinemia, hyperglycmia, 
insulin sensitivity, glucose disposal, dyslipidemia, and glycogen metabolism (25, 
28, 40, 58, 82, 88, 94, 96).  In the current study we examined several indicators 
of metabolic function within the skeletal muscle of obese mice.  The current data 
show that AMPK (p) T72 was elevated in ob/ob mice after 8 weeks of feeding 
with of β-GPA, which regulates glucose metabolism and gluconeogenesis (66).  
The rate limiting enzyme in fatty acid oxidation, ACC (p) T79 (83), was also 
elevated in the β-GPA fed ob/ob mice.  This suggests that 8 weeks of β-GPA 
feeding in ob/ob mice increases the efficiency of energy utilization within these 
animals. β-GPA fed ob/ob mice showed a 22.5 and 24% increase in PGC-1α and 
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COX IV, respectively, compared to control ob/ob mice (Fig 5).  PGC-1α and COX 
IV are good indicators of oxidative metabolism and mitochondrial function, 
respectively (11, 93). Together, these data suggest that 8 weeks of β-GPA 
feeding improves the metabolic function of skeletal muscle in ob/ob mice.   
  
 The increased potential for growth in ob/ob mice in the current study 
comes from the changes in mTOR signaling as a result of β-GPA feeding.   
Though no changes in raptor associated with mTOR were seen (Fig 7), there 
were alterations in the downstream machinery of mTORC1 signaling.  S6K1 (p) 
T389 was reduced to levels equivalent to those of the lean control mice (Fig 8b). 
S6K1 is used as an indicator of mTORC1 activity and is shown to be elevated in 
ob/ob mice (54).  Rivas et al. – 2009 showed that following a high fat diet, S6K1 
was elevated by 20% at T389 and this increase was totally reversed following 
exercise training (i.e. AMPK activation) (67).  Elevated S6K1 results in an 
increase in IRS-1 phosphorylation through negative feedback, decreasing insulin 
sensitivity and ultimately giving rise to insulin resistance in chronic situations 
(67).  In mice that are S6K1 deficient, there is a protective effect against obesity 
and insulin resistance because of an upregulation in oxidative phosphorylation 
and insulin sensitivity (90).  Therefore, its lower activation seen after 8 weeks of 
β-GPA in ob/ob mice in the current study is suggestive of more normalized 
mTOR signaling and some protective effect against insulin resistance.    
 
Interestingly, another mTORC1 substrate, 4E-BP1, was significantly 
increased in ob/ob mice fed β-GPA.  4E-BP1 regulates 40S ribosome binding to 
mRNA by increasing the availability of eIF-4E (78).  When 4E-BP1 is 
phosphorylated it releases eIF-4E allowing it to bind with eIF-4G and 
subsequently to the 40S ribosomal subunit (78).  A rise in 4E-BP1 was seen in 
our previous data after 2 weeks of injections with the AMPK kinase activator 
AICAR.  It is unclear at this time what role an increase in 4E-BP1 after treatment 
with an AMPK kinase activator means.  One thought is that 4E-BP1 acts to 
protect against excessive fat deposition and insulin resistance.  Le Bacquer et al 
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showed that in 4E-BP1 and 4E-BP2 double knock out (DKO) mice gained 
significantly more body mass as well as fat mass than their wild type 
counterparts (46).  When a high fat diet was fed to these DKO mice, insulin 
resistance was promoted to a greater extent than in the wild type mice (46).  It 
could be that the increase in 4E-BP1 that we observed is a protective measure to 
guard against the ob/ob mice regaining the fat mass that they had lost in regards 
to the β-GPA feeding. In DKO mice, S6K1 phosphorylation was significantly 
increased, suggesting that, though both are downstream of mTORC1, and may 
have a role in influencing each other (46).  Our current data are supportive of this 
thought given the reciprocal changes in 4E-BP1 and S6K1 with β-GPA treatment.  
 
We also examined 4E-BP1 within the eIF-4F complex in hopes of 
determining what role it plays in obese skeletal muscle. No significant changes 
occurred in eIF-4G or 4E-BP1 within the 4F complex following 8 weeks of feeding 
with β-GPA in ob/ob mice (Fig 6).  Though 4E-BP1 is phosphorylated by 
mTORC1, it is not the only signaling pathway that influences 4E-BP1.  Protein 
kinase Cδ (PKCδ) and the Erk pathway have also been shown to phosphorylate 
4E-BP1 (30, 45).  Insulin has also been shown to regulate the phosphorylation of 
4E-BP1 through the phosphitidylinositol 3-kinase (PI 3-kinase) signaling pathway, 
which is dependent on the phosphorylation and activation of protein kinase B 
(PKB)/Akt (22, 80, 91).  Had we analyzed skeletal muscle under fed conditions, 
we may have observed lower 4E-BP1 in our eIF-4E IPs, providing an alternative 
perspective to our treatment.  However, determining the exact role 4E-BP1 plays 
in obese skeletal muscle remains unclear at this time. 
 
 The other binding component of mTOR, rictor, is rapamycin insensitive.   
TORC2 controls the phosphorylation of PKB/Akt (70) that acts as a negative 
feedback regulator of TORC1 activation (6).  In the current data, there were no 
significant changes in Akt found in ob/ob mice after 8 the week β-GPA feeding.  
Rictor knock out (RImKO) mice function normally but display slight decreases in 
the amount of raptor (4).  In these RImKO mice Akt is still phosphorylated on Ser 
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473 so TORC2 is not solely responsible for Akt phosphorylation.  Also, Akt is 
hypothesized to play a role in the degree of raptor expression (4).  No change in 
Akt in the current study could account for the lack of change seen in raptor’s 
association with mTOR.  However, the downstream target of Akt, GSK3β, which 
inhibits glycogen synthase (33, 52), was significantly reduced in ob/ob mice after 
β-GPA feeding.  Since Akt was unchanged following β-GPA feeding in ob/ob 
mice in the current study, there could be another controller of GSK3 activity.  
S6K1 has been shown to regulate GSK3 upon the loss of TSC1-2 (99) in vitro, 
but more work needs to be done to determine any association in vivo between 
the two.    
 
 In conclusion, 8 weeks of β-GPA feeding caused decreases in body mass 
in ob/ob mice, which was accompanied by a slight increase in skeletal muscle 
mass.  The obese mouse muscle was more metabolically active following β-GPA 
feeding, evidenced by elevated AMPK (p) T72 and ACC (p) S79 levels.  β-GPA 
feeding did return certain downstream targets of mTORC 1 and 2 signaling 
(S6K1 (p) T389 and GSK3) to a level that is comparative with that of their lean 
counterparts, which exerts a potential protective effect against regaining fat 
mass.  Taken together, it is feasible that β-GPA feeding returns ob/ob skeletal 
muscle to a state in which growth can be attained under the proper stimulus (i.e. 
exercise or nutrition), not unlike their lean counterparts. 
 
 
 
 
 
 
 
 
 
 
 
  
 36 
Table 1 
 
O
F 
O
C
 
LF 
LC
 
 
41.39 ± 2.31*† 
58.29 ± 0.63* 
18.13 ± 1.15* 
31.29 ± 0.56 
B
ody W
eight 
(g) 
89.9 ± 6.0*† 
121.1 ± 9.3* 
92.4 ± 3.6 * 
158.5 ± 5.6 
M
uscle 
W
eight (m
g) 
17.8 ± 0.1 *† 
18.5 ± 0.1 
18.1 ± 0.2 * 
18.7 ± 0.1 
Tibial Length 
(m
m
) 
8.8 ± 0.5 * 
23.4 ± 2.0 
12.0 ± 0.5 * 
24.7 ± 1.1 
A
TP  
(µM
/g W
et w
t.) 
2.2 ± 0.2 * 
2.1± 0.2 * 
5.2 ± 0.2 
5.1 ± 0.2 
M
W
/B
W
 
5.0± 0.3 *† 
6.6 ± 0.5 * 
5.1± 0.2 * 
8.5± 0.3 
M
W
/TL 
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Figure 1 
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Figure 2 
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Figure 6 
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Figure 7 
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Figure 9 
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Figure Legends 
 
Figure 1.  Fasted mTOR signaling in lean and ob/ob skeletal muscles.  
Equal protein from lean and ob/ob male mice gastrocnemius, soleus, and tibialis 
anterior muscle homogenates were analyzed by Western blot methods for S6K1 
T389 and rpS6 S240/244 phosphorylation sites and normalized to GAPDH.  
LC=lean control, OC=ob/ob control.  Representative Western blots are shown. 
 
Figure 2.   Long term (8 wk) β-GPA feeding increases fasted AMPK 
signaling in ob/ob gastrocnemius muscle.  Following 8 weeks of feeding with 
1% β-GPA mixed chow, equal protein from lean and ob/ob male mice 
gastrocnemius muscle homogenates were analyzed by Western blot methods for 
AMPK T172 and ACC S79 phosphorylation sites and normalized to β-Tubulin 
(expressed as a percent of LC). LC=lean control, LF=β-GPA fed diet, OC=ob/ob 
control, OF=β-GPA fed diet.  Representative Western blots are shown. P < 0.05 
(n=8 per group, except OC n=7 in p-AMPK, 1 mouse was removed because it 
was more than 2 standard deviations from the mean). 
 
Figure 3. Long term (8 wk) β-GPA feeding decreases ATP levels in ob/ob 
gastrocnemius muscle.  Bioluminescence assay for quantitative determination 
of ATP with recombinant firefly luciferase and its substrate D-luciferin.  Amount of 
ATP was calculated in the experimental samples from a provided standard curve. 
Comparisons made using Two-way ANOVA with Bonferroni statistical analysis to 
LC.  LC=lean control, LF=β-GPA fed diet, OC=ob/ob control, OF=β-GPA fed diet. 
P < 0.05 (n=8 per group) 
 
Figure 4.  Long term (8 wk) β-GPA feeding attenuates weight gain in lean 
and ob/ob mice. During 8 weeks of feeding with 1% β-GPA mixed chow body 
weight was measured twice weekly as well as post feeding before sacrificing. 
Data shows mean weight per treatment plus standard error of the mean.  
Comparisons made using Two-way ANOVA with Bonferroni statistical analysis to 
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LC. LC=lean control, LF=β-GPA fed diet, OC=ob/ob control, OF=β-GPA fed diet.  
P < 0.05 versus LC (n=8 per group). 
 
Figure 5.  Food intake during (8 wk) β-GPA feeding between lean and ob/ob 
groups.  Mean weight of food from each cage eaten at weeks 2, 4, 6.5, and 7.5 
are shown with standard error of the mean. Comparisons made using Two-way 
ANOVA with Bonferroni statistical analysis to LC. LC=lean control, LF=β-GPA fed 
diet, OC=ob/ob control, OF=β-GPA fed diet.  P < 0.05 versus LC (n=8 per group). 
 
Figure 6. Long term (8 wk) β-GPA feeding does not change PGC-1α  
activation in ob/ob mice. Following 8 weeks of feeding with 1% β-GPA mixed 
chow, equal protein from lean and ob/ob male mice gastrocnemius muscle 
homogenates were analyzed by Western blot methods for PGC-1α and 
normalized to β-Tubulin.  The results are expressed as a percentage of LC. 
Percent difference of LF to LC and OF to OC is shown.  Representative Western 
blots are shown. Comparisons made using One-way ANOVA with Tukey’s 
statistical analysis. LC=lean control, LF=β-GPA fed diet, OC=ob/ob control, 
OF=β-GPA fed diet.  P < 0.05 versus LC (n=8 per group).  
 
Figure 7. Long term (8 wk) β-GPA feeding does not change COXIV 
activation in ob/ob mice. Following 8 weeks of feeding with 1% β-GPA mixed 
chow, equal protein from lean and ob/ob male mice gastrocnemius muscle 
homogenates were analyzed by Western blot methods for COX IV and 
normalized to β-Tubulin. The results are expressed as a percentage of LC. 
Percent difference of LF to LC and OF to OC is shown.  Representative Western 
blots are shown. Comparisons made using One-way ANOVA with Tukey’s 
statistical analysis. LC=lean control, LF=β-GPA fed diet, OC=ob/ob control, 
OF=β-GPA fed diet.  P < 0.05 versus LC (n=8 per group).   
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Figure 8. Long term (8 wk) β-GPA feeding does not alter eIF-4F complex 
formation in ob/ob mice. Following 8 weeks of feeding with 1% β-GPA mixed 
chow, equal protein from lean and ob/ob male mice gastrocnemius muscle 
homogenates was immunoprecipitated with an eIF-4E antibody, as described in 
Methods, and the immunoprecipitates (IP) were assessed for eIF-4G, 4E-BP1, 
and eIF-4E content by immunoblot (WB) analysis, and the ratio of eIF-4G to eIF-
4E and 4E-BP1 to eIF4E was calculated.  The results are expressed as a 
percentage of LC.  Representative Western blots are shown. Comparisons made 
using One-way ANOVA with Tukey’s statistical analysis. LC=lean control, LF=β-
GPA fed diet, OC=ob/ob control, OF=β-GPA fed diet.  P < 0.05 versus LC (n=8 
per group). 
 
Figure 9. Long term (8 wk) β-GPA feeding does not change raptor’s 
association with mTOR in ob/ob mice. Following 8 weeks of feeding with 1% 
β-GPA mixed chow, equal protein from lean and ob/ob male mice gastrocnemius 
muscle homogenates was immunoprecipitated with an mTOR antibody, as 
described in Methods, and the immunoprecipitates (IP) were assessed for raptor 
and mTOR content by immunoblot (WB) analysis, and the ratio of raptor to 
mTOR was calculated.  The results are expressed as a percentage of LC.  
Representative Western blots are shown. Comparisons made using One-way 
ANOVA with Tukey’s statistical analysis. LC=lean control, LF=β-GPA fed diet, 
OC=ob/ob control, OF=β-GPA fed diet.  P < 0.05 versus LC (n=8 per group). 
 
Figure 10. Long term (8 wk) β-GPA increases phosphorylated 4E-BP1 in 
ob/ob mice. Following 8 weeks of feeding with 1% β-GPA mixed chow, equal 
protein from lean and ob/ob male mice gastrocnemius muscle homogenates 
were analyzed by Western blot methods for 4E-BP1 (p), 4E-BP1 total, and 
normalized to β-Tubulin.  The results are expressed as a percentage of LC.  
Representative Western blots are shown. Comparisons made using One-way 
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ANOVA with Tukey’s statistical analysis. LC=lean control, LF=β-GPA fed diet, 
OC=ob/ob control, OF=β-GPA fed diet.  P < 0.05 versus LC (n=8 per group). 
 
Figure 11. Long term (8 wk) β-GPA decreases phosphorylated S6K1 in 
ob/ob mice. Following 8 weeks of feeding with 1% β-GPA mixed chow, equal 
protein from lean and ob/ob male mice gastrocnemius muscle homogenates 
were analyzed by Western blot methods for S6K1 T389, S6K1 total, rpS6 
S240/244, and normalized to β-Tubulin.  The results are expressed as a 
percentage of LC.  Representative Western blots are shown. Comparisons made 
using One-way ANOVA with Tukey’s statistical analysis. LC=lean control, LF=β-
GPA fed diet, OC=ob/ob control, OF=β-GPA fed diet.  P < 0.05 versus LC (n=8 
per group, except OC group in S6K1 T389 and rpS6 S240/244 n=7 because one 
mouse was more than two standard deviations away from the mean). 
 
Figure 12. Long term (8 wk) β-GPA does not change eEF-2 in ob/ob mice. 
Following 8 weeks of feeding with 1% β-GPA mixed chow, equal protein from 
lean and ob/ob male mice gastrocnemius muscle homogenates were analyzed 
by Western blot methods for eEF-2 and normalized to β-Tubulin.  The results are 
expressed as a percentage of LC.  Representative Western blots are shown. 
Comparisons made using One-way ANOVA with Tukey’s statistical analysis. 
LC=lean control, LF=β-GPA fed diet, OC=ob/ob control, OF=β-GPA fed diet.  P < 
0.05 versus LC (n=8 per group).  
 
Figure 13. Long term (8 wk) 1% β-GPA feeding does not change Akt 
signaling in ob/ob mice. Following 8 weeks of feeding with 1% β-GPA mixed 
chow, equal protein from lean and ob/ob male mice gastrocnemius muscle 
homogenates were analyzed by Western blot methods for Akt T308, Akt S473, 
Akt total, and normalized to β-Tubulin.  The results are expressed as a 
percentage of LC.  Representative Western blots are shown. Comparisons made 
using One-way ANOVA with Tukey’s statistical analysis. LC=lean control, LF=β-
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GPA fed diet, OC=ob/ob control, OF=β-GPA fed diet.  P < 0.05 versus LC (n=8 
per group, except OC group in Akt T308 and S473 n=7 because one mouse was 
more than two standard deviations away from the mean). 
 
Figure 14. Long term (8 wk) 1% β-GPA decreases GSK3β  in ob/ob mice. 
Following 8 weeks of feeding with 1% β-GPA mixed chow, equal protein from 
lean and ob/ob male mice gastrocnemius muscle homogenates were analyzed 
by Western blot methods for GSK3β and normalized to β-Tubulin.  The results 
are expressed as a percentage of LC.  Representative Western blots are shown. 
Comparisons made using One-way ANOVA with Tukey’s statistical analysis. 
LC=lean control, LF=β-GPA fed diet, OC=ob/ob control, OF=β-GPA fed diet.  P < 
0.05 versus LC (n=8 per group, except OC group n=7 because one mouse was 
more than two standard deviations away from the mean).  
 
Figure 15.  Proposed model of growth signaling in obese skeletal muscle 
following long term (8 wk) 1% β-GPA feeding. 
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Chapter 5:  Discussion of Findings 
Specific Aim 1:  
Our aim in using the well established AMPK agonist, β-GPA, was to 
counter the harmful side effects that obesity has on skeletal muscle.  Skeletal 
muscle that displays dyslipidemia, type 2 diabetes, and/or obesity has been 
shown to be less responsive to growth stimuli (40, 54, 90). β-GPA decreases 
muscle creatine levels (17, 73) by acting as a competitor.  ATP is then broken 
down creating higher levels of AMP, subsequently increasing AMPK activation 
(17, 95). Correspondingly, in the current study, 8 weeks of β-GPA feeding 
decreased ATP levels and increased AMPK (p) T172 and its substrate, ACC (p) 
T79, in lean and ob/ob mice (Fig 2a & b).  Though previously known to be an 
AMPK agonist (17-19, 73, 95), to our knowledge this is the first study to use β-
GPA to promote growth in obese skeletal muscle.  
 
 Reduced skeletal muscle size has been associated with obesity in animals 
(38, 39) and humans (57), despite an up-regulation of the growth-promoting 
mTOR pathway (6, 27, 38, 63, 67, 72), which these data corroborate (Table 1 
and Fig 8 & 9). However, skeletal muscle mass in relation with body mass 
increased in the β-GPA fed ob/ob mice by 5.7% (versus ob/ob control mice), 
however, this change did not reach significance (Table 1).  Given that the half-life 
of mixed mouse muscle is ~21 days (75, 87) and the dramatic reductions in body 
mass observed in the β-GPA fed ob/ob mice over the 8 week feeding period 
(Table 1), a greater increase in muscle mass was anticipated.  Muscle mass was 
also compared to tibial length for each animal (Table 1).  Muscle mass to tibial 
length was similar to the body weight comparisons in that no statistical 
significance was found. Ob/ob mice fed β-GPA did not differ significantly in body 
weight from lean control mice between 4-6 weeks of feeding (Fig 3).  After which, 
their food intake increased and they began to regain weight (Fig 3 & Fig 4).  It is 
possible that had we examined muscle weight between 4-6 weeks as opposed to 
8 weeks we would have seen a larger muscle mass to body mass ratio since the 
OF group gained weight after 6 weeks of feeding.   
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 Food intake was particularly difficult to control for the duration of the study.  
We only measured what food was left in the tray, not food on the floor of the 
cage, so there is sure to be a great deal of variability in our recordings.  To 
correct this issue in the future, food needs to be readily available to the animal in 
a matter that we can insure the exact amount being eaten, for example; placing 
food within a dish inside the cage itself.  
 
 In summary, 8 weeks of β-GPA feeding in ob/ob mice increases activation 
of AMPK (p) T72 and its substrate ACC (p) T79 (Fig 2a).  The efficacy of the 
treatment is supported by the significant decrease in the levels of ATP within β-
GPA fed groups (Fig 2b).  8 weeks of β-GPA feeding in ob/ob mice also causes 
dramatic decreases in body mass which is accompanied by slight increases in 
skeletal muscle mass (Table 1). Therefore, β-GPA feeding is an effective means 
by which to improve body composition in ob/ob mice. 
 
Specific Aim 2: 
 Previous research in obese skeletal muscle has focused mostly on 
understanding the metabolic state of the muscle, such as hyperinsulinemia, 
hyperglycemia, insulin sensitivity, glucose disposal, dyslipidemia, and glycogen 
metabolism (25, 28, 40, 58, 82, 88, 94, 96).  In the current study we examined 
several indicators of metabolic function within the skeletal muscle of obese mice.  
The current data show that AMPK (p) T72 was elevated in ob/ob mice after 8 
weeks of feeding with of β-GPA, which regulates glucose metabolism and 
gluconeogenesis (66).  The rate limiting enzyme in fatty acid oxidation, ACC (p) 
T79 (83), was also elevated in the β-GPA fed ob/ob mice.  This suggests that 8 
weeks of β-GPA feeding in ob/ob mice increases the efficiency of energy 
utilization within these animals. PGC-1α and COXIV are good indicators of 
oxidative metabolism and mitochondrial function, respectively (11, 93).  PGC-1α 
increased significantly in the lean mice fed β-GPA but no changes were seen in 
the ob/ob mice (Fig 5a).  No statistical significant changes were seen in COXIV in 
both groups (Fig 5b), however, there was a trend toward significance in both 
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groups.  Together, these data suggest that 8 weeks of β-GPA feeding improves 
the metabolic function of skeletal muscle in ob/ob mice.    
 
 The increased potential for growth in ob/ob mice in the current study 
comes from the changes in mTOR signaling as a result of β-GPA feeding.   
Though no changes in raptor associated with mTOR were seen (Fig 7), there 
were alterations in the downstream machinery of mTORC1 signaling.  S6K1 (p) 
T389 was reduced to levels equivalent to those of the lean control mice (Fig 8b). 
S6K1 is used as an indicator of mTORC1 activity and is shown to be elevated in 
ob/ob mice (54).  Rivas et al. – 2009 showed that following a high fat diet, S6K1 
was elevated by 20% at T389 and this increase was totally reversed following 
exercise training (i.e. AMPK activation) (67).  Elevated S6K1 results in an 
increase in IRS-1 phosphorylation through negative feedback; decreasing insulin 
sensitivity and ultimately giving rise to insulin resistance in chronic situations 
(67).  In mice that are S6K1 deficient, there is a protective effect against obesity 
and insulin resistance because of an upregulation in oxidative phosphorylation 
and insulin sensitivity (90).  Therefore, its lower activation seen after 8 weeks of 
β-GPA in ob/ob mice in the current study is suggestive of more normalized 
mTOR signaling and some protective effect against insulin resistance. 
 
Interestingly, another mTORC1 substrate, 4E-BP1 (p), was significantly 
increased in ob/ob mice fed β-GPA (Fig 9a).  No statistical significance was seen 
in total 4E-BP1.  4E-BP1 regulates 40S ribosome binding to mRNA by increasing 
the availability of eIF-4E (78).  When 4E-BP1 is phosphorylated it releases eIF-
4E allowing it to bind with eIF-4G and subsequently to the 40S ribosomal subunit 
(78).  A rise in 4E-BP1 was seen in our previous data after 2 weeks of injections 
with the AMPK kinase activator AICAR.  It is unclear at this time what role an 
increase in 4E-BP1 after treatment with an AMPK kinase activator means.  One 
thought is that 4E-BP1 acts to protect against excessive fat deposition and 
insulin resistance.  Le Bacquer et al showed that in 4E-BP1 and 4E-BP2 double 
knock out (DKO) mice gained significantly more body mass as well as fat mass 
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than their wild type counterparts (46).  When a high fat diet was fed to these DKO 
mice, insulin resistance was promoted to a greater extent than in the wild type 
mice (46).  It could be that the increase in 4E-BP1 that we observed is a 
protective measure to guard against the ob/ob mice regaining the fat mass that 
they had lost in regards to the β-GPA feeding. In DKO mice, S6K1 
phosphorylation was significantly increased, suggesting that, though both are 
downstream of mTORC1, and may have a role in influencing each other (46).  
Our current data are supportive of this thought given the reciprocal changes in 
4E-BP1 and S6K1 with β-GPA treatment. 
 
We also examined 4E-BP1 within the eIF-4F complex in hopes of 
determining what role it plays in obese skeletal muscle. No significant changes 
occurred in eIF-4G or 4E-BP1 within the 4F complex following 8 weeks of feeding 
with β-GPA in ob/ob mice (Fig 6). Though 4E-BP1 is phosphorylated by 
mTORC1, it is not the only signaling pathway that influences 4E-BP1.  Protein 
kinase Cδ (PKCδ) and the MAP kinase pathway have also been shown to 
phosphorylated 4E-BP1 (30, 45).  Insulin has also been shown to regulate the 
phosphorylation of 4E-BP1 through the phosphitidylinositol 3-kinase (PI 3-kinase) 
signaling pathway, which is dependent on the phosphorylation and activation of 
protein kinase B (PKB)/Akt (22, 80, 91).  Had we analyzed skeletal muscle under 
fed conditions, we may have observed lower 4E-BP1 in our eIF-4E IPs, providing 
an alternative perspective to our treatment.  However, determining the exact role 
4E-BP1 plays in obese skeletal muscle remains unclear at this time. 
 
 The other binding component of mTOR, rictor, is rapamycin insensitive.   
TORC2 controls the phosphorylation of PKB/Akt (70) that acts as a negative 
feedback regulator of TORC1 activation (6).  In the current data, there were no 
significant changes in Akt found in ob/ob mice after 8 the week β-GPA feeding.  
Rictor knock out (RImKO) mice function normally but display slight decreases in 
the amount of raptor (4).  In these RImKO mice Akt is still phosphorylated on Ser 
473 so TORC2 is not solely responsible for Akt phosphorylation.  Also, Akt is 
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hypothesized to play a role in the degree of raptor expression (4).  No change in 
Akt in the current study could account for the lack of change seen in raptor’s 
association with mTOR.  However, the downstream target of Akt, GSK3β, which 
inhibits glycogen synthase (33, 52), was significantly reduced in ob/ob mice after 
β-GPA feeding.  Since Akt was unchanged following β-GPA feeding in ob/ob 
mice in the current study, there could be another controller of GSK3 activity.  
S6K1 has been shown to regulate GSK3 upon the loss of TSC1-2 (99) in vitro, 
but more works needs to be done to determine any association in vivo. 
  
In future studies, we would propose to shorten the β-GPA feeding period 
to 4-6 weeks, because weight loss in the ob/ob was the greatest at this time.  To 
add to those data we would analyze other pathways that are known to influence 
4E-BP1 (Erk, PI-3 kinase, and/or PKCδ) in order to determine what is controlling 
the increase observed in 4E-BP1 following β-GPA feeding.  Moreover, examining 
the muscles under fed conditions could provide insight into how a known insulin 
resistant animal (ob/ob mouse) functions following β-GPA treatment, which would 
give a more complete picture of translation initiation within obese skeletal 
muscle. Given the normalization in skeletal muscle metabolism and growth 
signaling seen in ob/ob mice after β-GPA feeding in the current data, we would 
propose to subject these animals to an exercise regime or return them to a 
normal diet following 4-6 weeks of β-GPA feeding and examine how they 
respond to growth stimuli. 
 
 In summary, 8 weeks of β-GPA feeding caused decreases in body mass 
in ob/ob mice, which was accompanied by a slight increase in skeletal muscle 
mass.  The obese mouse muscle was more metabolically active following β-GPA 
feeding, evidenced by elevated AMPK (p) T72 and ACC (p) S79 levels.  β-GPA 
feeding did return certain downstream targets of mTORC 1 and 2 signaling 
(S6K1 (p) T389 and GSK3) to a level that is comparative with that of their lean 
counterparts, which exerts a potential protective effect against regaining fat 
mass.  Taken together, it is feasible that β-GPA feeding returns ob/ob skeletal 
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muscle to a state in which growth can be attained under the proper stimulus (i.e. 
exercise or nutrition), not unlike their lean counterparts. 
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